Are Peptides Legal in the US? Federal Law and All 50 States (2026)

Updated October 2026. Research use only.

Federal law: what actually restricts peptides

The Federal Food, Drug, and Cosmetic Act (FDCA) is the law that gives the FDA authority over drugs, and for research peptides it is almost the whole story. A product is a "drug" if it is intended to diagnose, cure, mitigate, treat or prevent disease, or "to affect the structure or any function of the body".¹ A new drug cannot be introduced into interstate commerce unless an FDA approval is in effect for it.² Most research peptides, including BPC-157, TB-500, CJC-1295 and ipamorelin, have never been approved for any use.

The key word is intended. The FDCA regulates what a product is sold and marketed to do, not the chemistry in the vial. That is why research vendors label everything "for research use only, not for human consumption": the label is an argument that the product is not a drug at all. In 2026 the FDA rejected that argument in every warning letter it sent to a research-peptide seller. The 31 March letters put it this way: "Despite statements on your product labeling marketing your products for 'Research Use Only,' ... evidence obtained from your website establishes that your products are intended to be drugs for human use."⁶ Dosing instructions, before and after claims, bundled bacteriostatic water and, in two August letters, a "peptide calculator" were all treated as evidence of human use.⁷

Who the law reaches: the prohibited acts are about commerce, introducing or delivering an unapproved or misbranded drug, and also receiving one in interstate commerce and passing it on "for pay or otherwise".⁴ That second clause is how a buyer who resells becomes a defendant: in April 2026 a Utah physician was indicted for obtaining imported peptides and selling them to more than 200 patients.¹⁵ No federal statute makes simple personal possession or use of a non-controlled research peptide a crime. Importing is a separate issue: the FDA says that "in most circumstances, it is illegal for individuals to import drugs ... into the U.S. for personal use", outside a narrow, discretionary exception for serious conditions with no US treatment.⁵ The Bureau's peptide and GLP-1 enforcement tracker lists each action with its date and the agency's own copy.

The one peptide with its own federal statute: HGH

Human growth hormone is the clear exception to the "it is a marketing question" pattern. Under 21 U.S.C. § 333(e), added by the Anti-Drug Abuse Act of 1988, whoever "knowingly distributes, or possesses with intent to distribute, human growth hormone for any use in humans other than the treatment of a disease or other recognized medical condition", where that use is FDA-approved and ordered by a physician, faces up to 5 years in prison, or up to 10 years if the offence involves someone under 18.³ The statute defines human growth hormone as "somatrem, somatropin, or an analogue of either of them". Note what it does not cover: simple possession for your own use is not in the text, and secretagogues such as sermorelin, CJC-1295, ipamorelin and GHRP-6, which prompt the pituitary to release its own hormone, are not growth hormone. They fall under the general FDCA rules above. Some states schedule HGH themselves, which can make possession a state offence; the state table shows which.

When a peptide is also an FDA-approved drug

A short list of peptides are approved prescription drugs: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta SV and Egrifta WR, for excess abdominal fat in adults with HIV-associated lipodystrophy) and bremelanotide (Vyleesi, for acquired, generalised hypoactive sexual desire disorder in premenopausal women), plus older peptide hormones for narrow indications.⁸ For these the molecule has an approved status for specific uses at specific doses, and a vendor selling the same sequence as a lyophilised "research chemical" is selling an unapproved version of an approved drug. Several states also make possessing a prescription-only drug without a prescription an offence, which reaches a semaglutide or tirzepatide vial.

Retatrutide is not on that list. It is an investigational Eli Lilly drug that, as Fortune reported in August 2026, "hasn't been approved by regulators anywhere in the world"; Lilly plans to seek FDA approval in early 2027.¹⁶ Anything sold as retatrutide today is unapproved by definition. The guides on compounded semaglutide, compounded tirzepatide and compounded retatrutide cover the compounding side of each.

State law: what actually differs

Federal law is the floor and, for research peptides, most of the building. States add three things. First, their own controlled-substance schedules: six of them (Colorado, Idaho, Massachusetts, Minnesota, Nevada and West Virginia) put human growth hormone in their own schedules, several list hCG, Georgia names semaglutide, tirzepatide and sermorelin as prescription-only dangerous drugs, and no state has scheduled BPC-157, TB-500 or ipamorelin. A second group (Idaho, Indiana, Kentucky, Louisiana, Minnesota, Nevada, New Jersey and others) makes possessing any prescription-only drug without a prescription an offence, which reaches semaglutide or tirzepatide vials but not research peptides that are not approved drugs. Second, pharmacy and medical boards: several boards of pharmacy have taken positions on compounded semaglutide and tirzepatide, and medical boards discipline prescribers who administer unapproved compounds, which is how peptide clinics and medspas get into trouble at state level. In 2026 three medical boards went further and told licensees they may not prescribe, administer or dispense research-grade peptides: Alabama (26 May), South Carolina (August) and Mississippi (19 August, jointly with its nursing and pharmacy boards). Third, consumer-protection law: Connecticut's attorney general sued a "research grade" GLP-1 seller under the state's unfair trade practices act in May 2025 and settled in August 2025, a route any state can take without a peptide-specific statute.

The table below summarises what the Bureau found for every state on 28 September 2026, and each state name links to a page with the citations, board statements, telehealth position, enforcement record and sources for that state.

All 50 states, with a page for each

"Not found" means the Bureau could not locate a provision after searching the state code and board sites, not that one does not exist. Each state page lists what was searched and links every source.

FDA compounding: 503A, 503B and the category lists

Compounding is a separate legal track from research sales, and most confusion about "are peptides legal" comes from mixing the two. Two sections of the FDCA, not of the Drug Quality and Security Act as often stated, set the rules: section 503A (21 U.S.C. § 353a, from 1997) for state-licensed pharmacies compounding for individual patients, and section 503B (21 U.S.C. § 353b, added in 2013) for outsourcing facilities that compound in bulk.⁹

A 503A pharmacy may compound from a bulk ingredient only if it has a USP or NF monograph, is a component of an FDA-approved drug, or is on the FDA's 503A bulks list. A 503B facility needs the ingredient on the clinical-need bulks list or the drug on the FDA shortage list.⁹ Because the 503A list is still being built by rulemaking, the FDA runs an interim policy for nominated ingredients:¹⁰

• Category 1: nominated and under evaluation. The FDA does not intend to act against pharmacies compounding with these while it decides.
• Category 2: nominated, but the FDA has identified "significant safety risks". Not covered by the interim policy.
• Category 3: nominated without enough supporting information. Not covered.

Two points people miss. Leaving Category 2 does not put a peptide into Category 1 or onto the list: a law firm summarising the April 2026 change put it as "such removal does not, in itself, establish eligibility for compounding under Section 503A".¹¹ And since 7 January 2025, newly nominated ingredients are not placed in any category at all, so a fresh nomination no longer opens a door.¹⁰

A research vendor shipping a lyophilised peptide labelled for laboratory use is not a compounding pharmacy and is not operating under 503A or 503B at all. A licensed pharmacy compounding BPC-157 into a prescription today is outside both, which is a more direct problem for the pharmacy than anything the research label raises for a vendor. The July 2026 advisory committee page has the full tallies and the history.

What changed in 2026

More moved in 2026 than in the previous decade, in two directions at once: enforcement against research sellers and mass compounders tightened, while the FDA's leadership signalled it might loosen compounding for some older research peptides.

• February: HHS Secretary Robert F. Kennedy Jr. told a podcast audience he was a "big fan" of peptides and called the 2023 compounding restrictions an overreach, as reported by BioPharma Dive.²¹
• 3 March: the FDA warned 30 telehealth companies over the marketing of compounded GLP-1 drugs; 25 more followed on 16 June, 55 in the year.²²
• 31 March: the first 2026 batch of warning letters to research-peptide sellers, rejecting the "research use only" defence. Further letters followed on 17 June and 24 August.^6,7
• April: a Utah physician was indicted for selling imported peptides to more than 200 patients.¹⁵
• 15 to 22 April: the FDA took 12 peptides out of 503A Category 2 after their nominations were withdrawn, and scheduled advisory committee reviews for them.^11,14
• 30 April: the FDA proposed keeping semaglutide, tirzepatide and liraglutide off the 503B bulks list: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." Comments closed 30 July; no final decision has been published.^19,20
• 23 to 24 July: the Pharmacy Compounding Advisory Committee voted to recommend BPC-157, KPV and TB-500 (each 8 to 6), MOTS-c (7 to 5), Semax (8 to 5) and Epitalon (7 to 4) for the 503A list, and rejected emideltide, against the recommendation of FDA staff. The vote is advisory; the next step is a proposed rule with public comment.^12,13
• 30 July: the owner of Paradigm Peptides was sentenced to 70 months in federal prison for selling unapproved and illegally imported drugs, including products with forged lab certificates.²³
• 12 August: Eli Lilly filed six lawsuits over retatrutide sales and said it had referred more than 200 entities to the FDA, the Justice Department, state attorneys general and licensing boards.^16,24
• May to August: medical boards in Alabama, South Carolina and Mississippi told licensees they may not prescribe, administer or dispense research-grade peptides (details and sources on each state page).
• 18 September: the FDA warned Empower Pharmacy, a large Houston compounder, for making what it called essentially copies of semaglutide and tirzepatide, drawing a line between patient-specific compounding and mass production.²⁵

Where that leaves things on 4 October 2026: the Federal Register shows no proposed rule adding any peptide to the 503A list, so none of the six recommended peptides can be lawfully compounded yet, and the research channel is under more pressure than at any point before.¹²

Regulatory status by category: quick reference

Reading a listing's legal status

• Is the molecule an approved drug (semaglutide, tirzepatide, tesamorelin, bremelanotide), an unapproved research peptide, or human growth hormone? Each sits under different rules.
• Does the listing give human dosing, before and after claims, or bundle injection supplies? The FDA treats those as proof the product is sold as a drug.
• Is it shipped from abroad? Personal importation of unapproved drugs is illegal in most circumstances.
• Does your state schedule the compound, or make possessing a prescription drug without a prescription an offence? Check its state page.
• Is "research use only" being read as permission? It is the seller's marketing category, not a legal status for the buyer.

Legal status and product quality are separate questions. The peptide testing guide covers what a certificate of analysis can and cannot prove.

FAQ

Is it legal to buy research peptides in the US?

Buying and possessing a research peptide that is not a controlled substance is not a federal crime, and the Bureau found no state that criminalises it for unscheduled research peptides. The legal exposure sits with sellers and suppliers: selling an unapproved peptide for human use is a violation, and the FDA's 2026 letters say the research label is no defence. Importing from abroad is generally illegal, and a few states add their own rules for specific compounds.

Does 'research use only' labelling make a peptide legal to use on yourself?

No. The label describes the seller's marketing claim, not a permission for the buyer. Personal use of a non-controlled research peptide is not itself a federal offence, but nothing about the label makes it approved, tested for human use or legally sanctioned.

Is BPC-157 legal?

No state has scheduled BPC-157, so possessing it is not a state offence anywhere the Bureau checked. Federally it is an unapproved drug, so selling it for human use is a violation. Licensed pharmacies cannot compound it yet: the FDA's advisory committee recommended adding it to the 503A list in July 2026 by 8 votes to 6, but no rule has followed. It is also prohibited in sport.

Is HGH legal without a prescription?

No. Federal law makes it a felony to knowingly distribute human growth hormone, or possess it with intent to distribute, for anything other than an FDA-approved use ordered by a physician, with up to 5 years in prison. Several states also schedule HGH, which can make simple possession a state offence. Secretagogues such as sermorelin and ipamorelin are not HGH and fall under the general drug rules.

Can I import peptides for personal use?

The FDA says that "in most circumstances, it is illegal for individuals to import drugs or devices into the U.S. for personal use". It describes a narrow, discretionary exception: a product for a serious condition with no effective US treatment, no unreasonable risk, generally no more than a three-month supply, and a US physician overseeing treatment or evidence it began abroad. That is a description of when the FDA may choose not to act, not a right to import, and research peptides bought online rarely fit it.

Are all research peptides treated the same under federal law?

No. Human growth hormone has its own statute, 21 U.S.C. 333(e). Approved peptide drugs such as semaglutide and tirzepatide carry prescription-drug rules and their own compounding history. Unapproved research peptides fall under the general new-drug rules, and their compounding status differs peptide by peptide, from still in Category 2 (kisspeptin-10) to recommended for listing (BPC-157, TB-500).

Do peptides show up on drug tests?

On a standard workplace panel, no. Federally regulated panels screen for marijuana, cocaine, opioids, phencyclidine and amphetamines including MDMA, and no peptide is on that list.²⁷ Sports testing is different: the 2026 WADA Prohibited List names growth hormone releasing hormone analogues including CJC-1295, sermorelin and tesamorelin, growth hormone secretagogues, and non-approved substances, prohibited at all times.²⁶ Anyone in a tested sport should assume detection is possible.

Are peptides natty?

In any tested federation, no. Growth hormone releasing factors and secretagogues are on the WADA Prohibited List at all times,²⁶ so using them is a doping violation however they are described. The argument that a secretagogue is natural because it prompts your own pituitary does not hold, because the rules prohibit the class rather than the mechanism. Outside tested competition the word has no fixed definition.

Which peptides are FDA approved?

A short list: semaglutide and tirzepatide (type 2 diabetes and weight management, plus newer indications), tesamorelin (excess abdominal fat in adults with HIV-associated lipodystrophy, not weight loss) and bremelanotide, known as PT-141 (acquired, generalised hypoactive sexual desire disorder in premenopausal women), plus older peptide hormones for narrow uses. BPC-157, TB-500, ipamorelin, CJC-1295, MOTS-c, epitalon and retatrutide have no FDA approval for any use.

Can you buy peptides over the counter?

Not injectable drug peptides. Approved peptide drugs need a prescription, and unapproved research peptides have no lawful pharmacy channel. What is sold over the counter legally are cosmetic peptides in skincare, such as topical copper peptides, and collagen peptide supplements, which are regulated as cosmetics and foods rather than drugs.

What changed for peptides in 2026?

Enforcement tightened and compounding policy started to move. The FDA sent several rounds of warning letters to research-peptide sellers rejecting the research-use-only defence, warned 55 telehealth companies over compounded GLP-1s, and proposed keeping semaglutide and tirzepatide off the 503B list. At the same time it took 12 peptides out of Category 2, and in July its advisory committee recommended six of them, including BPC-157 and TB-500, for the 503A list. No rule has followed yet.

Sources

1. 21 U.S.C. § 321(g)(1), definition of drug (FDCA section 201(g)(1)). law.cornell.edu
2. 21 U.S.C. § 355(a), new drugs (FDCA section 505(a)). law.cornell.edu
3. 21 U.S.C. § 333(e), prohibited distribution of human growth hormone. law.cornell.edu
4. 21 U.S.C. § 331, prohibited acts (FDCA section 301). law.cornell.edu
5. US Food and Drug Administration. Personal importation. fda.gov
6. US Food and Drug Administration. Warning letter to Gram Peptides, 31 March 2026. fda.gov
7. US Food and Drug Administration. Warning letter to Royal Peptides LLC, 24 August 2026. fda.gov
8. FDA drug labels via openFDA: tesamorelin, bremelanotide, tirzepatide. tesamorelin, bremelanotide, tirzepatide
9. 21 U.S.C. § 353a (FDCA section 503A) and § 353b (section 503B). 353a, 353b
10. US Food and Drug Administration. Interim policy on compounding using bulk drug substances under section 503A, guidance, January 2025. fda.gov
11. Goodwin Procter. FDA signals potentially evolving stance toward compounding of certain peptides, May 2026. goodwinlaw.com
12. STAT. FDA advisory panel rejects compounding of one peptide, backs another, 24 July 2026. statnews.com
13. US Food and Drug Administration. July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov
14. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of 22 April 2026), and the 503A categories list (updated 14 May 2026). fda.gov, categories list
15. Partnership for Safe Medicines. Over 200 patients bought unapproved imported peptides from a now-indicted Utah physician, 6 April 2026. safemedicines.org
16. Fortune. Lilly escalates its fight against black-market weight-loss shots, 12 August 2026. fortune.com
17. US Food and Drug Administration. Pharmacy Compounding Advisory Committee, 29 October 2024, final summary minutes. fda.gov
18. US Food and Drug Administration. Pharmacy Compounding Advisory Committee, 4 December 2024, transcript. fda.gov
19. US Food and Drug Administration. FDA proposes to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, 30 April 2026. fda.gov
20. US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (shortage end dates). fda.gov
21. BioPharma Dive. FDA moves toward easing restrictions on certain peptides, 16 April 2026. biopharmadive.com
22. US Food and Drug Administration. FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s, 3 March 2026; RAPS on the 16 June round. fda.gov, raps.org
23. CBS News. Judge sentences peptide vendor to nearly 6 years in prison, July 2026. cbsnews.com
24. CBS News. Eli Lilly takes aim at illicit market for its experimental weight-loss drug, August 2026. cbsnews.com
25. US Food and Drug Administration. Warning letter to Empower Clinic Services LLC dba Empower Pharmacy, 18 September 2026. fda.gov
26. World Anti-Doping Agency. 2026 Prohibited List. wada-ama.org
27. 49 CFR 40.85, drugs and cutoff concentrations in federally regulated urine drug tests. ecfr.gov

Every federal fact above was checked against the linked source on 4 October 2026; state facts carry their own sources and check dates on each state page. If a rule has changed, email bureau@peptidebureau.com with the link and the page will be corrected and dated.